Pacira BioSciences, Inc. (PCRX) stock forecast & analysis
36.39
NasdaqGS · USDDelayed by 15 minutes
Up: +11.19, +44.4%
1 analysis
Latest analysis: · verdict locked
- Open
- 36.32
- Previous close
- 25.20
- Day range
- 36.27 – 36.40
- 52-week range
- 18.80 – 36.46
- Volume (shares)
- 28.88M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 39.91M
- P/E ratio
- 103.97
- Dividend yield
- 0.00%
- Beta
- 0.25
- Market cap
- 1.45B
Market Scanner’s AI analysis of Pacira BioSciences, Inc. (PCRX), updated October 2026: Pacira Biosciences (PCRX) acquisition by Viatris dominates recent coverage, alongside mixed financial performance and technical overbought signals.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Pacira BioSciences, Inc. (PCRX) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Pacira Biosciences (PCRX) acquisition by Viatris dominates recent coverage, alongside mixed financial performance and technical overbought signals.
Recent analyses for PCRX covered the company's acquisition by Viatris, which has led to analyst rating changes. Financially, the company reported a year-over-year revenue increase but also a net loss in the prior fiscal year, with current margins showing modest profitability. Technical indicators suggest the stock is trading in a strong uptrend and may be overextended in the short term.
PCRX news & sentiment
News coverage focused heavily on the acquisition of Pacira Biosciences by Viatris, leading to analyst rating changes. Social media discussion was not covered in the provided notes.
PCRX technical picture
PCRX's price action showed a strong uptrend, trading significantly above its 50-day and 200-day simple moving averages. Momentum indicators like the MACD were positive, though RSI, MFI, and Bollinger Bands suggested the stock may be overextended in the short term.
Fundamentals
The company reported a year-over-year increase in quarterly revenue, with a notable improvement in net income for the most recent quarter. However, the prior fiscal year saw a significant net loss, and current operating and profit margins are modest.
Factors discussed — upside
- Quarterly revenue increased 6.2% year-over-year.
- Net income showed a notable increase in the most recent quarter.
- Stock price trading significantly above 50-day and 200-day SMAs.
- Positive MACD indicating bullish momentum.
Factors discussed — risks
- Company experienced a net loss in fiscal year 2024.
- RSI and MFI indicate an overbought condition.
- Stock price trading above the upper Bollinger Band.
- Analyst downgrades following acquisition announcement.
- Acquisition by Viatris
- Financial performance
- Technical indicators
- Analyst ratings
Summary updated .
PCRX technical indicators
Common technical indicators for PCRX, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 25.38 | Price above |
| 10-day exponential moving average | 27.13 | Price above |
| Relative strength index (14-day) | 85.07 | Overbought |
| MACD line (12/26/9) | 0.8728 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 20.44 – 30.57 | Price above the upper band |
Analyses
Recent PCRX.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-09 PCRX.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Pacira BioSciences, Inc.?
- The bull case for PCRX centers on its recent quarterly revenue growth and a notable increase in net income, alongside strong technical signals including a price significantly above key moving averages and positive MACD momentum.
- What are the risks for Pacira BioSciences, Inc.?
- Risks for PCRX include a net loss reported in fiscal year 2024, technical indicators suggesting an overbought condition with the price above the upper Bollinger Band, and analyst downgrades following the acquisition announcement.
- Is Pacira BioSciences, Inc. bullish or bearish?
- Recent AI analyses of Pacira BioSciences, Inc. examined factors on both sides. Discussed upside: The bull case for PCRX centers on its recent quarterly revenue growth and a notable increase in net income, alongside strong technical signals including a price significantly above key moving averages and positive MACD momentum. Discussed risks: Risks for PCRX include a net loss reported in fiscal year 2024, technical indicators suggesting an overbought condition with the price above the upper Bollinger Band, and analyst downgrades following the acquisition announcement. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Pacira BioSciences, Inc.?
- News coverage focused heavily on the acquisition of Pacira Biosciences by Viatris, leading to analyst rating changes. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Pacira BioSciences, Inc.?
- Every analysis of Pacira BioSciences, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Pacira BioSciences, Inc.?
The bull case for PCRX centers on its recent quarterly revenue growth and a notable increase in net income, alongside strong technical signals including a price significantly above key moving averages and positive MACD momentum.
What are the risks for Pacira BioSciences, Inc.?
Risks for PCRX include a net loss reported in fiscal year 2024, technical indicators suggesting an overbought condition with the price above the upper Bollinger Band, and analyst downgrades following the acquisition announcement.
Is Pacira BioSciences, Inc. bullish or bearish?
Recent AI analyses of Pacira BioSciences, Inc. examined factors on both sides. Discussed upside: The bull case for PCRX centers on its recent quarterly revenue growth and a notable increase in net income, alongside strong technical signals including a price significantly above key moving averages and positive MACD momentum. Discussed risks: Risks for PCRX include a net loss reported in fiscal year 2024, technical indicators suggesting an overbought condition with the price above the upper Bollinger Band, and analyst downgrades following the acquisition announcement. These are descriptive observations, not a recommendation.
What is the latest sentiment on Pacira BioSciences, Inc.?
News coverage focused heavily on the acquisition of Pacira Biosciences by Viatris, leading to analyst rating changes. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Pacira BioSciences, Inc.?
Every analysis of Pacira BioSciences, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh PCRX.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.